Based on our years of in-depth research and analysis of patient outcomes and new discoveries, we know that a “one-size-fits-all” approach does not apply in today’s world of medicine. Rather, with advanced diagnostic tools that enable us to extract detailed information at the molecular level and scientific expertise to understand the information, we are customizing each patient’s treatment regimen for a targeted, precision medicine approach.
Targeting treatment to each patient’s disease holds the most promise of cure.
Every case of myeloma is unique. Disease characteristics, including genetic mutations, individual risk factors such as other medical conditions, family history and one’s environment – all play a role in defining the nuances of each patient’s disease. The same type of cancer, such as myeloma, is different for each individual.
Like other cancers, myeloma is characterized by genetic abnormalities, or mutations, that result from damage to normal cells. In particular, the biologic mechanisms that control normal cell growth are affected. This wreaks havoc with the function of the cells through altered patterns of gene activity, known as gene expression.
The characteristics of each individual’s genetic make-up and the genetic changes that give rise to cancer result in a unique profile of behavior for each person’s disease. In order to develop a personalized treatment plan for each patient that has the best chance of being effective, it is necessary to identify the unique characteristics and behavior profile.
Information obtained from advanced diagnostic testing at the Myeloma Institute, including gene expression profiling (GEP), DNA and RNA sequencing, allows Myeloma Institute doctors to develop individualized, precision medicine plans that incorporate targeted therapies for each patient. (link here to Advanced Diagnostics brochure)
Our advanced diagnostics make it possible to predict whether a given drug or treatment regimen will be effective for a patient. Thus, we can custom-tailor treatment so that patients receive only those drugs that will be most effective for them. This approach maximizes disease kill and minimizes unnecessary toxicity from drugs that are unlikely to be effective. It builds upon our strategy of assigning patients to clinical trials based on high-risk disease or low-risk disease factors.
The Myeloma Institute has a state-of-the-art laboratory dedicated to molecular diagnostics discovery. Our scientists are continually refining existing and developing new methodologies for defining the nuances of each individual’s disease, with the goal of optimizing each patient’s care and outcome.